Table of Contents

1. Overview & Manufacturers
2. Active Ingredients & How They Work
3. Efficacy & Weight Loss Results
4. Pros & Cons Comparison
5. Current Trends: Which Product Is Hotter Right Now?
6. Common & Severe Side Effects
7. Summary Comparison Table

1. Overview & Manufacturers

Both Mounjaro and Wegovy belong to a class of incretin-based injectables administered once weekly. While widely discussed together, they are produced by distinct pharmaceutical companies and hold different primary FDA approvals:

• Wegovy: Manufactured by Novo Nordisk (Denmark). It was specifically FDA-approved for chronic weight management in adults and adolescents aged 12 and older with obesity or overweight conditions.
• Mounjaro: Manufactured by Eli Lilly and Company (USA). It is FDA-approved to treat Type 2 Diabetes (its weight-loss brand twin, marketed under the same active formula, is Zepbound). Mounjaro is frequently prescribed off-label for weight management due to its significant weight loss efficacy.

2. Active Ingredients & How They Work

The primary technical difference between these two treatments lies in their cellular target mechanisms:

• Wegovy (Semaglutide): A single-action GLP-1 receptor agonist. It mimics the natural GLP-1 hormone, slowing gastric emptying, signaling fullness to the brain, and reducing appetite.
• Mounjaro (Tirzepatide): A dual-action GIP / GLP-1 receptor agonist. By targeting both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, it provides a synergistic effect on insulin secretion, glucagon regulation, and satiety signals.

3. Efficacy & Weight Loss Results

Head-to-head clinical data consistently shows that tirzepatide (Mounjaro) delivers greater average weight loss percentages compared to semaglutide (Wegovy):

• Wegovy (Semaglutide 2.4 mg): Clinical trials (STEP programs) demonstrate an average weight reduction of approximately 15% of body weight over 68 weeks.
• Mounjaro / Zepbound (Tirzepatide 15 mg): Clinical trials (SURMOUNT programs) demonstrate an average weight reduction of up to 20.9% to 22.5% of body weight over 72 weeks.

4. Pros & Cons Comparison

Wegovy

• Pros:
  • FDA-approved explicitly for weight management and cardiovascular risk reduction.
  • Proven 20% reduction in major adverse cardiovascular events (MACE).
  • Approved for adolescents (ages 12+).
• Cons:
  • Slightly lower overall weight loss percentage compared to tirzepatide.
  • Frequent supply shortages due to unprecedented demand.

Mounjaro

• Pros:
  • Dual-action mechanism yields superior average weight loss (~20%+).
  • Highly effective at regulating blood sugar levels and improving insulin sensitivity.
• Cons:
  • Primarily indicated for Type 2 Diabetes (weight-loss use may require off-label prescribing or Zepbound alternative).
  • Requires careful dose titration across six strength tiers.

5. Current Trends: Which Product Is Hotter Right Now?

While Wegovy (and its diabetes counterpart, Ozempic) kickstarted the modern GLP-1 surge, Mounjaro (Tirzepatide) currently holds the spotlight as the faster-growing favorite.

• Why Mounjaro/Tirzepatide leads current demand: Clinical data highlighting higher average weight loss percentages has prompted a shift among physicians and patients toward tirzepatide.
• Wegovy’s persistent strength: Wegovy maintains a strong position due to its approved indications for pediatric weight management and heart disease risk reduction.

6. Common & Severe Side Effects

Because both medications delay stomach emptying, side effects center around the gastrointestinal tract.

Common Side Effects (70%–80% of users)

• Nausea and vomiting
• Diarrhea or constipation
• Stomach pain and acid reflux/heartburn
• Fatigue and headaches

Rare but Severe Side Effects

• Pancreatitis: Inflammation of the pancreas requiring immediate medical care.
• Gallbladder problems: Gallstones or inflammation (cholecystitis).
• Kidney impairment: Secondary to dehydration from severe nausea/vomiting.
• Gastrointestinal obstruction: Gastroparesis (stomach paralysis) or severe bowel blockages.
• Boxed Warning (Thyroid Tumors): Both carry a FDA black box warning regarding C-cell thyroid cancer risks observed in animal models.

7. Summary Comparison Table

Feature	Wegovy	Mounjaro
Manufacturer	Novo Nordisk	Eli Lilly
Active Ingredient	Semaglutide	Tirzepatide
Drug Class	GLP-1 Receptor Agonist	Dual GIP / GLP-1 Receptor Agonist
FDA Approval Status	Chronic Weight Loss	Type 2 Diabetes (Zepbound for weight)
Avg. Weight Loss	~15%	~20%–22.5%
Administration	Subcutaneous once weekly	Subcutaneous once weekly

Disclaimer: Always consult a licensed healthcare professional prior to starting or changing any injectable weight management therapy.